Off-Label Use of Botulinum Toxin in Dermatology—Current State of the Art

Lewandowski, Miłosz; Świerczewska, Zuzanna; Barańska‐Rybak, Wioletta

doi:10.3390/molecules27103143

Cited by 14 publications

(16 citation statements)

References 115 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Występuje siedem różnych rodzajów egzotoksyn: A, B, C, D, E, F, G, z czego komercyjnie używa się BoNT-A i BoNT-B. (3,6) Pierwszy raz została użyta w 1980r. przez Edwarda Schantza i Alana B. Scotta w terapii leczenia zeza.…”

Section: Toksyna Botulinowaunclassified

“…przez Edwarda Schantza i Alana B. Scotta w terapii leczenia zeza. (3,7) Obecnie toksyna botulinowa jest szeroko stosowana w różnych dziedzinach medycyny, m.in. w medycynie estetycznej, neurologii, okulistyce, dermatologii, ginekologii, ortopedii, otolaryngologii, chirurgii, stomatologii.…”

Section: Toksyna Botulinowaunclassified

“…w medycynie estetycznej, neurologii, okulistyce, dermatologii, ginekologii, ortopedii, otolaryngologii, chirurgii, stomatologii. (3,7) Pomimo, iż okres działania toksyny botulinowej po podaniu jest ograniczony czasowo, jej podanie wydaje się być korzystną metodą leczenia dla pacjenta. Działanie toksyny botulinowej utrzymuje się przez cały kilkumiesięczny okres, przez co pacjent nie musi podporządkowywać swojego życia do terapii np.…”

Section: Toksyna Botulinowaunclassified

See 2 more Smart Citations

Application of botulinum toxin in the treatment of bruxism

MILANOWSKA

DUDZIŃSKA

GRUDZIŃSKA

et al. 2022

J Educ Health Sport

View full text Add to dashboard Cite

Bruxism is a commonly reported functional para-function of the oral cavity. Its symptoms are quite characteristic and include, above all, excessive clenching and grinding of the teeth. (2) Other complaints most frequently reported by patients are headaches, pain in the temporomandibular joint, excessive tooth abrasion, damage to dentures, waking up at night, visual effect - the so-called "square jaw". The etiology is multifactorial therefore it is difficult to treat its symptoms. Botulinum toxin is a neurotoxin produced by the anaerobic bacteria Clostridium botulinum. Its mechanism is based on the reversible inhibition of acetylcholine release in neuromuscular junctions. Intramuscular injection of botulinum toxin is one of the treatments of bruxism. So far, this method is used off-label. Looking at the promising results of randomized studies on the use of botulinum toxin in bruxism, this may change in the near future. As shown by previous studies, it is not an ideal method, but nevertheless it is one of the most effective and the best for the patient. The downside to the use of botulinum toxin in the treatment of bruxism symptoms are, inter alia, contraindications to the use of this drug and the duration of its action - 3-6 months. This systematic review of selected articles and studies aims to examine the available literature in order to determine the effectiveness of the use of botulinum toxin in the treatment of bruxism and to assess whether it is currently the most effective method. Pubmed and Google Scholar were searched for literature.

show abstract

Section: Toksyna Botulinowaunclassified

See 1 more Smart Citation

Application of botulinum toxin in the treatment of bruxism

MILANOWSKA

DUDZIŃSKA

GRUDZIŃSKA

et al. 2022

J Educ Health Sport

View full text Add to dashboard Cite

show abstract

“…Serotypes A and B are currently in clinical usage, but botulinum neurotoxin A (BoNT-A) is the most commonly used [15,16]. Concerning temporary muscle paralysis capability, wide clinical treatment has been adopted [16][17][18]. Apart from inhibiting acetylcholine release from a presynaptic neuromuscular junction, studies found that BoNT-A can reduce skin inflammation by inhibiting mast cell degranulation and blocking cholinergic stimuli to apocrine and eccrine glands [19].…”

Section: Introductionmentioning

confidence: 99%

Botulinum Toxin Type A for the Treatment of Skin Ulcers: A Review Article

Winayanuwattikun

Vachiramon

2022

Toxins

View full text Add to dashboard Cite

The normal biological wound healing process consists of three precisely and highly programmed phases that require optimal conditions including internal and external factors. Any negative factors that disrupt the sequence or time frame of the healing mechanism can result in a non-healing wound or chronic ulcers. Botulinum neurotoxin A (BoNT-A) which is generally known as anti-contraction of muscles has been reported as a successful treatment in various types of chronic ulcers. The aim of this study is to review the outcome of treatment with BoNT-A for chronic skin ulcers. The results demonstrated some positive effects of BoNT-A on chronic ulcers. Ischemic ulcers secondary to Raynaud’s phenomenon seem to be the most promising type of ulcers that have benefited from BoNT-A. The rationale behind using BoNT-A to fasten the wound healing process is also discussed. Further clinical trial studies should be conducted to affirm the efficacy of wound healing using BoNT-A administration.

show abstract

“…There are several conditions for which BoNT is not yet approved for clinical use, but off-label use has been presented, with beneficial effects, for example, in dermatology [ 33 , 34 , 35 ], primary headaches other than migraine [ 36 ], depression [ 37 ], and neuropathic pain [ 38 , 39 ]. One large area in which the off-label use of BoNT has been practiced for the last two decades is dermatology, for various conditions that appear with or without itch [ 40 , 41 , 42 , 43 ].…”

Section: Introductionmentioning

confidence: 99%

How Does Botulinum Toxin Inhibit Itch?

Gazerani

2022

Toxins

View full text Add to dashboard Cite

Two decades after reports of the anti-pruritic effects of botulinum neurotoxins (BoNTs), there is still no approved product for the anti-itch indication of BoNTs, and most clinical case reports still focus on the off-label use of BoNTs for various itchy conditions. Few randomized clinical trials have been conducted with controversial results, and the beneficial effects of BoNTs against itch are mainly based on case studies and case series. These studies are valuable in presenting the potential application of BoNTs in chronic pruritic conditions, but due to the nature of these studies, they are categorized as providing lower levels of evidence or lower grades of recommendation. To obtain approval for the anti-pruritic indication of BoNTs, higher levels of evidence are required, which can be achieved through conducting large-scale and well-designed studies with proper control groups and established careful and reliable primary and secondary outcomes. In addition to clinical evidence, presenting the mechanism-based antipruritic action of BoNTs can potentially strengthen, accelerate, and facilitate the current efforts towards further investments in accelerating the field towards the potential approval of BoNTs for itchy conditions. This review, therefore, aimed to provide the state-of-the-art mechanisms underlying the anti-itch effect of BoNTs from basic studies that resemble various clinical conditions with itch as a hallmark. Evidence of the neuronal, glial, and immune modulatory actions of BoNTs in reducing the transmission of itch are presented, and future potential directions are outlined.

show abstract

Off-Label Use of Botulinum Toxin in Dermatology—Current State of the Art

Cited by 14 publications

References 115 publications

Application of botulinum toxin in the treatment of bruxism

Application of botulinum toxin in the treatment of bruxism

Botulinum Toxin Type A for the Treatment of Skin Ulcers: A Review Article

How Does Botulinum Toxin Inhibit Itch?

Contact Info

Product

Resources

About